Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial

OBJECTIVE: In the SENSCIS trial in subjects with systemic sclerosis–associated interstitial lung disease (SSc‐ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categor...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M., Mayes, Maureen D., Kreuter, Michael, Volkmann, Elizabeth R., Aringer, Martin, Castellvi, Ivan, Cutolo, Maurizio, Stock, Christian, Schoof, Nils, Alves, Margarida, Raghu, Ganesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048624/
https://www.ncbi.nlm.nih.gov/pubmed/33142016
http://dx.doi.org/10.1002/art.41576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048624/
https://www.ncbi.nlm.nih.gov/pubmed/33142016
http://dx.doi.org/10.1002/art.41576

Ejemplares similares